Revvity, Inc. (RVTY) Price/FCF Ratio: 22.16
Is Revvity, Inc.’s Price/FCF ratio high or low?
Revvity, Inc.'s Price/FCF ratio of 22.16 is 83% below its 5-year average of 127.13, near the low end of its 5-year range (12.38–1391.78).
1.50% above its 12-month average of 21.83.
RVTY Price/FCF Ratio Chart
RVTY Average Price/FCF Ratio Chart
RVTY Current vs Average Price/FCF Ratio Chart
RVTY Price/FCF Ratio Metrics
PRICE/FCF RATIO
22.16
PRICE/FCF RATIO AVG TTM
21.83
PRICE/FCF RATIO AVG 3Y
44.48
PRICE/FCF RATIO AVG 5Y
23.00
PRICE/FCF RATIO AVG 10Y
28.63
PRICE/FCF RATIO AVG 15Y
27.76
PRICE/FCF RATIO AVG 20Y
25.12
CURRENT VS TTM AVG
+1.50%
CURRENT VS 3Y AVG
-50.18%
CURRENT VS 5Y AVG
-3.66%
CURRENT VS 10Y AVG
-22.60%
CURRENT VS 15Y AVG
-20.18%
CURRENT VS 20Y AVG
-11.78%
RVTY Competitors' Price/FCF Ratio
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 22.16 | 21.83 | 44.48 | 23.00 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.86 | 17.13 | 29.64 | 17.62 |
| Baxter International Inc. (BAX)vs › | $10.19B | 14.76 | 39.04 | 30.97 | 30.26 |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 18.11 | 19.06 | 30.90 | 40.40 |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 22.27 | 33.83 | 71.56 | 57.97 |
| Solventum Corporation (SOLV)vs › | $12.91B | N/A | 116.92 | 65.01 | 65.01 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 22.81 | 16.39 | 22.69 | 28.29 |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 17.94 | 21.95 | 22.58 | 22.80 |
| Tempus AI, Inc. (TEM)vs › | $8.51B | N/A | N/A | N/A | N/A |
| DaVita Inc. (DVA)vs › | $13.46B | 9.64 | 8.03 | 8.73 | 8.76 |
Free Cash Flow Valuation
P/FCF Ratio
22.2
FCF Yield
4.51%
Revvity, Inc. Price/FCF Ratio Formula & Definition
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Price/FCF Ratio FAQ
- What is the Price/FCF ratio for Revvity, Inc. (RVTY)?
- The Price/FCF ratio for RVTY stock is 22.16.
- Is Revvity, Inc.'s Price/FCF ratio high or low?
- Revvity, Inc.'s Price/FCF ratio of 22.16 is 83% below its 5-year average of 127.13, near the low end of its 5-year range (12.38–1391.78).
- What is the TTM average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The TTM average Price/FCF ratio for RVTY stock is 21.83.
- What is the 3Y average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The 3Y average Price/FCF ratio for RVTY stock is 44.48.
- What is the 5Y average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The 5Y average Price/FCF ratio for RVTY stock is 23.00.
- What is the 10Y average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The 10Y average Price/FCF ratio for RVTY stock is 28.63.
- What is the 15Y average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The 15Y average Price/FCF ratio for RVTY stock is 27.76.
- What is the 20Y average Price/FCF ratio for Revvity, Inc. (RVTY)?
- The 20Y average Price/FCF ratio for RVTY stock is 25.12.
Revvity, Inc. Price/FCF Ratio History
| DATE | PRICE/FCF RATIO |
|---|---|
| 2026-06-17 | 22.16 |
| 2026-06-16 | 22.93 |
| 2026-06-15 | 22.78 |
| 2026-06-12 | 22.57 |
| 2026-06-11 | 23.00 |
| 2026-06-10 | 22.94 |
| 2026-06-09 | 23.59 |
| 2026-06-08 | 22.72 |
| 2026-06-05 | 22.28 |
| 2026-06-04 | 23.19 |
| 2026-06-03 | 22.89 |
| 2026-06-02 | 22.74 |
| 2026-06-01 | 22.77 |
| 2026-05-29 | 23.68 |
| 2026-05-28 | 22.93 |
| 2026-05-27 | 21.92 |
| 2026-05-26 | 21.93 |
| 2026-05-22 | 21.96 |
| 2026-05-21 | 21.60 |
| 2026-05-20 | 21.47 |
| 2026-05-19 | 21.72 |
| 2026-05-18 | 21.63 |
| 2026-05-15 | 21.28 |
| 2026-05-14 | 21.83 |
| 2026-05-13 | 21.52 |
| 2026-05-12 | 22.49 |
| 2026-05-11 | 21.93 |
| 2026-05-08 | 22.39 |
| 2026-05-07 | 21.91 |
| 2026-05-06 | 21.96 |
| 2026-05-05 | 20.46 |
| 2026-05-04 | 19.17 |
| 2026-05-01 | 19.21 |
| 2026-04-30 | 19.20 |
| 2026-04-29 | 18.23 |
| 2026-04-28 | 18.88 |
| 2026-04-27 | 19.24 |
| 2026-04-24 | 19.23 |
| 2026-04-23 | 19.32 |
| 2026-04-22 | 20.90 |
| 2026-04-21 | 20.89 |
| 2026-04-20 | 20.62 |
| 2026-04-17 | 20.82 |
| 2026-04-16 | 19.84 |
| 2026-04-15 | 20.59 |
| 2026-04-14 | 20.73 |
| 2026-04-13 | 20.53 |
| 2026-04-10 | 19.90 |
| 2026-04-09 | 20.05 |
| 2026-04-08 | 20.04 |
| 2026-04-07 | 19.46 |
| 2026-04-06 | 19.57 |
| 2026-04-02 | 19.71 |
| 2026-04-01 | 19.49 |
| 2026-03-31 | 19.42 |
| 2026-03-30 | 18.79 |
| 2026-03-27 | 18.60 |
| 2026-03-26 | 19.31 |
| 2026-03-25 | 19.47 |
| 2026-03-24 | 19.38 |
| 2026-03-23 | 19.32 |
| 2026-03-20 | 19.05 |
| 2026-03-19 | 19.01 |
| 2026-03-18 | 18.82 |
| 2026-03-17 | 19.36 |
| 2026-03-16 | 19.17 |
| 2026-03-13 | 18.97 |
| 2026-03-12 | 18.79 |
| 2026-03-11 | 19.87 |
| 2026-03-10 | 20.01 |
| 2026-03-09 | 20.41 |
| 2026-03-06 | 20.24 |
| 2026-03-05 | 21.40 |
| 2026-03-04 | 21.83 |
| 2026-03-03 | 21.27 |
| 2026-03-02 | 21.19 |
| 2026-02-27 | 21.79 |
| 2026-02-26 | 21.94 |
| 2026-02-25 | 21.63 |
| 2026-02-24 | 21.64 |
| 2026-02-23 | 22.98 |
| 2026-02-20 | 23.74 |
| 2026-02-19 | 23.65 |
| 2026-02-18 | 23.13 |
| 2026-02-17 | 22.49 |
| 2026-02-13 | 22.73 |
| 2026-02-12 | 22.62 |
| 2026-02-11 | 23.93 |
| 2026-02-10 | 24.79 |
| 2026-02-09 | 24.33 |
| 2026-02-06 | 24.04 |
| 2026-02-05 | 23.55 |
| 2026-02-04 | 24.57 |
| 2026-02-03 | 23.93 |
| 2026-02-02 | 25.34 |
| 2026-01-30 | 25.75 |
| 2026-01-29 | 25.68 |
| 2026-01-28 | 26.30 |
| 2026-01-27 | 27.12 |
| 2026-01-26 | 27.15 |
| 2026-01-23 | 27.63 |
| 2026-01-22 | 27.87 |
| 2026-01-21 | 27.58 |
| 2026-01-20 | 26.48 |
| 2026-01-16 | 26.62 |
| 2026-01-15 | 27.29 |
| 2026-01-14 | 26.39 |
| 2026-01-13 | 26.07 |
| 2026-01-12 | 24.59 |
| 2026-01-09 | 24.71 |
| 2026-01-08 | 24.07 |
| 2026-01-07 | 24.37 |
| 2026-01-06 | 24.86 |
| 2026-01-05 | 24.15 |
| 2026-01-02 | 23.23 |
| 2025-12-31 | 22.90 |
| 2025-12-30 | 23.06 |
| 2025-12-29 | 22.98 |
| 2025-12-26 | 22.90 |
| 2025-12-24 | 22.90 |
| 2025-12-23 | 23.09 |
| 2025-12-22 | 23.14 |
| 2025-12-19 | 22.78 |
| 2025-12-18 | 22.78 |
| 2025-12-17 | 22.90 |
| 2025-12-16 | 22.78 |
| 2025-12-15 | 23.45 |
| 2025-12-12 | 23.78 |
| 2025-12-11 | 24.59 |
| 2025-12-10 | 24.50 |
| 2025-12-09 | 23.38 |
| 2025-12-08 | 23.62 |
| 2025-12-05 | 23.85 |
| 2025-12-04 | 24.27 |
| 2025-12-03 | 24.44 |
| 2025-12-02 | 24.31 |
| 2025-12-01 | 24.24 |
| 2025-11-28 | 24.71 |
| 2025-11-26 | 24.77 |
| 2025-11-25 | 24.98 |
| 2025-11-24 | 23.80 |
| 2025-11-21 | 23.26 |
| 2025-11-20 | 22.25 |
| 2025-11-19 | 21.83 |
| 2025-11-18 | 22.02 |
| 2025-11-17 | 21.55 |
| 2025-11-14 | 21.95 |
| 2025-11-13 | 22.10 |
| 2025-11-12 | 22.28 |
| 2025-11-11 | 22.32 |
| 2025-11-10 | 21.84 |
| 2025-11-07 | 21.48 |
| 2025-11-06 | 21.19 |
| 2025-11-05 | 21.91 |
| 2025-11-04 | 21.70 |
| 2025-11-03 | 21.73 |
| 2025-10-31 | 21.87 |
| 2025-10-30 | 21.27 |
| 2025-10-29 | 22.27 |
| 2025-10-28 | 22.54 |
| 2025-10-27 | 22.71 |
| 2025-10-24 | 23.11 |
| 2025-10-23 | 22.80 |
| 2025-10-22 | 22.36 |
| 2025-10-21 | 22.64 |
| 2025-10-20 | 22.27 |
| 2025-10-17 | 21.83 |
| 2025-10-16 | 21.97 |
| 2025-10-15 | 21.53 |
| 2025-10-14 | 21.30 |
| 2025-10-13 | 21.26 |
| 2025-10-10 | 20.63 |
| 2025-10-09 | 21.42 |
| 2025-10-08 | 21.45 |
| 2025-10-07 | 21.31 |
| 2025-10-06 | 21.82 |
| 2025-10-03 | 21.98 |
| 2025-10-02 | 21.37 |
| 2025-10-01 | 21.44 |
| 2025-09-30 | 20.48 |
| 2025-09-29 | 19.68 |
| 2025-09-26 | 19.64 |
| 2025-09-25 | 19.41 |
| 2025-09-24 | 19.74 |
| 2025-09-23 | 20.03 |
| 2025-09-22 | 20.16 |
| 2025-09-19 | 20.27 |
| 2025-09-18 | 20.51 |
| 2025-09-17 | 19.95 |
| 2025-09-16 | 19.93 |
| 2025-09-15 | 19.63 |
| 2025-09-12 | 19.37 |
| 2025-09-11 | 20.02 |
| 2025-09-10 | 19.28 |
| 2025-09-09 | 19.87 |
| 2025-09-08 | 20.16 |
| 2025-09-05 | 20.25 |
| 2025-09-04 | 20.03 |
| 2025-09-03 | 19.48 |
| 2025-09-02 | 20.53 |
| 2025-08-29 | 21.06 |
| 2025-08-28 | 20.85 |
| 2025-08-27 | 20.70 |
| 2025-08-26 | 21.32 |
| 2025-08-25 | 21.53 |
| 2025-08-22 | 22.00 |
| 2025-08-21 | 20.96 |
| 2025-08-20 | 21.43 |
| 2025-08-19 | 21.36 |
| 2025-08-18 | 20.96 |
| 2025-08-15 | 21.21 |
| 2025-08-14 | 20.90 |
| 2025-08-13 | 21.25 |
| 2025-08-12 | 20.56 |
| 2025-08-11 | 20.05 |
| 2025-08-08 | 20.29 |
| 2025-08-07 | 20.20 |
| 2025-08-06 | 20.07 |
| 2025-08-05 | 20.72 |
| 2025-08-04 | 20.26 |
| 2025-08-01 | 20.24 |
| 2025-07-31 | 20.16 |
| 2025-07-30 | 20.84 |
| 2025-07-29 | 21.67 |
| 2025-07-28 | 21.80 |
| 2025-07-25 | 23.78 |
| 2025-07-24 | 23.39 |
| 2025-07-23 | 22.81 |
| 2025-07-22 | 22.05 |
| 2025-07-21 | 20.81 |
| 2025-07-18 | 21.39 |
| 2025-07-17 | 21.93 |
| 2025-07-16 | 21.77 |
| 2025-07-15 | 22.00 |
| 2025-07-14 | 22.59 |
| 2025-07-11 | 23.28 |
| 2025-07-10 | 23.49 |
| 2025-07-09 | 22.97 |
| 2025-07-08 | 23.09 |
| 2025-07-07 | 22.64 |
| 2025-07-03 | 23.24 |
| 2025-07-02 | 23.15 |
| 2025-07-01 | 22.72 |
| 2025-06-30 | 22.19 |
| 2025-06-27 | 22.44 |
| 2025-06-26 | 22.66 |
| 2025-06-25 | 22.41 |
| 2025-06-24 | 22.11 |
| 2025-06-23 | 21.78 |
| 2025-06-20 | 21.79 |
| 2025-06-18 | 21.66 |
| 2025-06-17 | 21.60 |
| 2025-06-16 | 22.10 |
| 2025-06-13 | 21.46 |
| 2025-06-12 | 21.95 |
| 2025-06-11 | 22.04 |
| 2025-06-10 | 22.08 |
| 2025-06-09 | 21.31 |
| 2025-06-06 | 21.10 |
| 2025-06-05 | 20.76 |
Showing the most recent 260 of 4,967 data points. The chart above shows the full history.
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh